The Rising Concerns Surrounding Gabapentin Use
Gabapentin, initially approved by the Food and Drug Administration (FDA) for seizure disorders and postherpetic neuralgia – nerve pain following shingles – has seen a dramatic increase in prescriptions over the last decade. Although often viewed as a safer alternative to opioids for chronic pain management, emerging research raises concerns about potential cognitive risks, prescribing patterns, and the need for careful patient monitoring.
Gabapentin’s Increasing Popularity
Prescriptions for gabapentin more than doubled between 2010 and 2024, with the number of Americans taking the medication nearly tripling from 5.8 million to 15.5 million. By 2024, gabapentin was the fifth most dispensed drug in U.S. Retail pharmacies. This surge coincides with growing awareness of the opioid epidemic and a subsequent shift towards alternative pain management strategies.
Cognitive Risks: A Growing Concern
Recent studies have linked chronic gabapentin use to increased risks of cognitive impairment and dementia, particularly in younger individuals. A study published in Regional Anesthesia & Pain Medicine found that chronic pain patients prescribed six or more gabapentin prescriptions had a more than doubled risk of dementia and a more than tripled risk of mild cognitive impairment compared to those not prescribed the medication, among those aged 35 to 49. The risk increased with higher prescription frequency, with those receiving 12 or more prescriptions experiencing even greater incidence of these conditions.
Prescribing Cascades and Unintended Consequences
An analysis in JAMA Network Open highlighted the potential for prescribing cascades, where side effects of one medication are treated with another, leading to further complications. The study of military veterans treated with gabapentin found that clinicians often attributed fluid build-up to conditions like congestive heart failure rather than considering gabapentin-induced edema, leading to inappropriate diuretic prescriptions.
Global Uncertainty in Gabapentinoid Use
A 2025 review in the European Journal of Pain revealed a recurring theme of uncertainty among clinicians worldwide regarding the optimal approach to starting, monitoring, and tapering gabapentinoid use. This lack of clear guidance contributes to inconsistent prescribing practices and potential patient harm.
Gabapentin and Self-Harm
Research from the U.K., published in the BMJ, examined the relationship between gabapentin treatment and self-harm. The study found an increased risk of self-harm in the 90 days before treatment, during early treatment, and again after treatment cessation, highlighting the importance of careful patient monitoring throughout the course of gabapentin therapy.
Common Side Effects and Considerations
Common side effects of gabapentin include drowsiness, dizziness, blurry vision, and difficulty with coordination and concentration. Given the potential risks and side effects, it’s crucial for medical professionals to carefully weigh the benefits and risks of gabapentin treatment and ensure that the treatment doesn’t create more problems than it solves.
What is Gabapentin Used For?
Gabapentin is an anticonvulsant medication used to treat seizures and nerve pain caused by shingles. It works by calming overactive nerve activity in the brain and nervous system.